Drug Search Results
More Filters [+]

Evacetrapib

Alternative Names: evacetrapib, ly2484595
Latest Update: 2023-07-18
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CETP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Evacetrapib

Countries in Clinic: Japan

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Dyslipidemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-132045

P3

Active

Unknown

None

JapicCTI-111527

P2

Active

Dyslipidemia

None

Recent News Events